In the fourth quarter and full-year 2024 financial results, Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, announced several notable developments. The year 2024 saw the in-licensing of ALXN1840, the initiation of two first-in-human radiopharma Phase 1 clinical trials, and the strengthening of the company. More details regarding the financial results are yet to be provided.

Monopar Therapeutics plans to submit a New Drug Application (NDA) to the FDA for Wilson Disease treatment ALXN1840 in early 2026. Wilson Disease is a rare genetic condition that causes damage from toxic copper build-up in the body. ALXN1840 is a potent binder and mobilizer of copper. In October 2024, Monopar announced a worldwide exclusive license to ALXN1840 with Alexion, AstraZeneca Rare Disease.

Monopar Therapeutics (NASDAQ:MNPR) has had its "buy" rating reiterated by HC Wainwright's equities research analysts. They have given a price target of $40.00 for the stock, which suggests a potential upside of 9.86% from the company's current price. In addition, Piper Sandler has also reiterated an "overweight" rating for Monopar Therapeutics, with a higher target price of $76.00. The stock of Monopar Therapeutics opened at $36.4.

From the information provided, Monopar Therapeutics has recently reported its third-quarter financial results for the year 2024. The company has also made significant strides in its product pipeline with the in-licensing of ALXN-1840, a late-stage drug for Wilson disease, from Alexion, AstraZeneca Rare Disease. Additionally, Monopar Therapeutics has active and enrolling patients in two novel radiopharma clinical trials targeting advanced solid cancers. The specifics of the financial results, however, were not disclosed in the provided information.

This is an official communication from Monopar Therapeutics Inc. which states that the company has released its financial results for the fourth quarter and the full year ended December 31, 2024, on March 31, 2025. The details of the financial results are provided in Exhibit 99.1 attached to this communication. The information in this document and the attached exhibit are not intended to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, or to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, unless expressly mentioned in such a filing.

1) Brief Summary: The company has seen robust performance over the past month (27.22%) and quarter (69.10%) with a significant increase in trading volume (Rel Volume: 2.26). The company has a healthy level of institutional ownership (42.25%), and insider ownership is also strong (35.63%). However, the company's Return on Equity (ROE) and Return on Investment (ROI) are negative, indicating a lack of profitability. The company also shows a negative EPS surprise, which suggests that it didn't meet the market's expectations. The insider trading activities indicate a significant level of confidence among the top management. 2) MARKET_SCORE: Given the positive performance metrics but concerning profitability indicators, we estimate a 70% likelihood of an upward move. Hence, MARKET_SCORE: 70

3) PRICE_TARGET: The current price of the stock is $39.005. Based on the positive performance and volume indicators, we project a 20% increase in the stock price, giving a new price target of $46.8. Thus, PRICE_TARGET: $46.8

4) AI_RPT_HEADLINE: "Strong Ownership and Performance Metrics Offset by Profitability Concerns"

-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes

====================================================== : 2025-04-02 12:30:59

# Analysis Completed Elapsed Time: 47.46 seconds